The 7 Things to Tell Your Psychiatrist About Your Medication That Most Patients Skip

Your prescriber makes decisions about your medication based on what you tell them. Not what actually happened since your last appointment, but what you remember, feel safe sharing, or think is worth mentioning. That gap is not a personal failure. It is a structural problem that affects almost everyone on psychiatric medication.

The quarterly appointment model gives you 15 minutes, once every three months, to reconstruct what happened across 90 daily treatment days. The data that actually drives good prescribing decisions happens in real time: when your side effects peaked, whether you missed doses and why, what changed in your sleep before your mood shifted. Most of that information never makes it into the appointment.

This is not a guide to getting better at talking to your doctor. It is a map of the specific clinical information that changes prescribing decisions and that most patients consistently skip.

Why These 7 Things Get Skipped

Most patients do not intentionally withhold information from their prescriber. The skipping happens for three reasons: time pressure (a 15-minute appointment is not long enough to surface everything), social dynamics (patients want to seem compliant), and a genuine lack of awareness that the information matters clinically.

The result is that prescribers make dose decisions, switching decisions, and adherence assessments based on an incomplete picture. Research examining nearly 185,000 patients found that almost 60% discontinue antidepressants within three months of starting treatment. Most of those dropouts happen between appointments, in a window the prescriber never sees. Better information would not prevent all of those discontinuations. But it would prevent some of them.

The Exact Timing Pattern of Your Side Effects

When a prescriber asks about side effects, most patients answer with a category: “I have nausea” or “I am having trouble sleeping.” That information tells the prescriber the side effect exists. It does not tell them what they need to know to respond to it.

The clinically useful version of that report is: when the side effect occurs relative to dosing, how long it lasts, whether it is improving or worsening over weeks, and at what severity. This distinction matters because the same side effect with different timing patterns has different clinical responses.

Nausea that peaks two hours after dosing and resolves by hour four is a pharmacokinetic response to peak plasma concentration. It may be managed by taking the medication with food or adjusting the dosing time. Nausea that persists around the clock and is worsening in week four is a different clinical signal that may warrant a dose reduction or medication change.

“When a patient tells me they have nausea, the first question I have is when does it happen and is it getting better or worse over weeks,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Most patients do not track this, so I am working from a vague report rather than a clinical picture. The pattern is what tells me what to do next.”

Research on antidepressant adherence has found that adverse events are among the primary drivers of early discontinuation, with fear of side effects inhibiting treatment initiation and actual side effects driving dropout. Many of those discontinuations are preventable with the right clinical intervention, but only if the prescriber knows about the side effect in time to act.

Your Real Adherence Record

This one is the hardest for most patients to report honestly. There is a social pressure to tell your prescriber you are taking your medication as prescribed. Most patients want to be seen as compliant. Most patients are also not perfectly compliant: they miss doses, take doses at the wrong time, or briefly stop and restart without telling anyone.

These adherence patterns are not moral failures. They are clinical data. And they change what your prescriber can conclude from your treatment response.

A patient who has missed four doses in the past two weeks and reports that the medication does not seem to be working is not experiencing treatment failure. They are experiencing under-exposure. The prescriber who does not know about the missed doses may interpret the data as evidence that the current dose needs to increase, or that a medication switch is warranted. Both conclusions would be clinically wrong.

Honest adherence reporting means: how many doses you missed, why you missed them (side effects, forgetting, schedule disruption, or a decision to reduce because you felt better), and whether the pattern is regular or occasional. Your prescriber needs this information not to judge you, but because it changes the clinical interpretation of everything else you report.

Sleep Changes, and When They Started

Sleep changes are among the earliest signals of antidepressant response, and one of the most consistently underreported. Most patients do not connect their sleep to their medication because sleep feels like a separate category from mood. Psychiatrically, it is not.

Sleep disturbances are among the most prevalent features of depressive episodes according to NIH clinical guidance, and changes in sleep quality often precede changes in mood on antidepressants. When sleep begins to improve in the first two weeks of treatment, that movement is one of the earliest indicators that the medication may be working. When sleep deteriorates after an initial period of improvement, that can signal a coming mood decline that has not yet registered in the patient’s self-reported mood scores.

Your prescriber needs to know not just whether you are sleeping, but when sleep quality changed, whether that change corresponded with a dose change or a life event, and what the trajectory has been week by week. Most patients wait until mood changes are obvious before reporting anything. By the time the mood signal is visible, the sleep signal has often been present for weeks.

Everything You Are Taking

Psychiatric medications interact with a wide range of substances, including many that patients do not think of as medications. This category includes over-the-counter drugs (NSAIDs, antihistamines, decongestants, acid reducers), supplements, cannabis, and alcohol.

Supplements: St. John’s Wort is a well-documented CYP450 inducer that reduces SSRI plasma concentrations. The NIH National Center for Complementary and Integrative Health documents that several popular supplements, including St. John’s Wort, interact with psychiatric medications in clinically significant ways. Melatonin, omega-3 fatty acids, and other common supplements are also in active clinical discussion.

Cannabis and CBD: Research published in the Journal of Personalized Medicine found that CBD and THC inhibit cytochrome enzyme activity and can increase concentrations of sertraline and escitalopram, with coadministration of CBD and CYP2C19-metabolized SSRIs increasing the risk of adverse effects including dizziness and fatigue. Initiating, stopping, or changing cannabis use can significantly affect how an antidepressant behaves in your system. Patients routinely underreport cannabis use in clinical settings. Your prescriber needs this information not to judge your choices, but to understand what the medication is actually doing in your body.

Alcohol: Alcohol is a CNS depressant that interacts with sedating psychiatric medications and can worsen depression over time. The interaction pattern is worth discussing openly with your prescriber, including quantity and frequency.

How the Medication Is Affecting Your Daily Function

Standard psychiatric assessments like the PHQ-9 measure depression symptom severity. They do not measure how the medication is affecting your ability to concentrate at work, your patience with people around you, your motivation to do things you used to find meaningful, or your physical energy.

These functional domains are clinically meaningful and routinely underreported. A patient whose PHQ-9 score has improved but who still cannot sustain focus, complete tasks, or maintain relationships has achieved partial treatment response, not remission. That partial response may be addressable with a different dose, different timing, or adjunctive treatment, but only if the prescriber knows it exists.

Tell your prescriber how the medication is affecting function in specific domains: focus and cognition (is thinking clearer or is there brain fog?), motivation (has initiative returned or are you going through the motions?), physical energy (is tiredness lifting or has fatigue increased?), and social function (is connection easier or harder?). These are not soft outcomes. They are clinical signals that determine whether treatment is achieving its actual goals.

What “Feeling Better” Specifically Means to You

Psychiatric treatment that does not know what it is aiming for cannot tell you whether it is working. Yet most patients have never explicitly defined what “better” looks like for their situation.

“Feeling better than I do now” is not a treatment target. A treatment target is: being able to get through a full workday without emotional exhaustion. Falling asleep before midnight consistently. Having energy to be present with my kids in the evening. Being able to manage conflict without days of recovery.

APA practice guidelines for major depressive disorder describe remission as the absence of symptoms and return to full baseline functioning, which is a meaningfully higher bar than symptom reduction alone. Your prescriber can adjust medication toward a vague direction. They can calibrate it toward a specific target. Telling them what you are actually trying to get back, or get to for the first time, gives them a clinical objective to optimize against.

If You Have Changed Your Dose or Are Thinking About Stopping

This is the most important item on this list and the one patients are most reluctant to share.

Many patients self-adjust their dose. They feel better and quietly reduce the medication, skip doses on days when they feel good, or gradually taper on their own because they do not want to have the conversation with their prescriber. They are often planning to stop the medication before their prescriber knows they are considering it.

All of these decisions matter clinically. Self-reducing or stopping an antidepressant without prescriber oversight carries real risk: discontinuation symptoms (brain zaps, nausea, dizziness, rebound anxiety) for medications that require tapering, and relapse risk that is meaningfully higher for patients who stop abruptly than for those who taper under supervision.

Your prescriber’s job when you bring this up is not to lecture you or demand you keep taking the medication. Their job is to give you the clinical picture: what supervised tapering looks like, what the relapse risk data says for your situation, and what the plan would be if symptoms return. That conversation cannot happen if the decision to stop never gets mentioned.

How SiggyMD Captures This Data Continuously

The 15-minute quarterly appointment is structurally unable to surface most of what is listed above. By the time the appointment arrives, side effect timing patterns are a vague memory, missed doses have been reconstructed into a more favorable narrative, sleep trajectory has been compressed into “pretty good, I think,” and the conversation about wanting to stop never quite happens.

SiggyMD’s daily check-ins capture structured data on side effect timing, adherence, sleep quality, functional domains, and treatment goals every day. The licensed prescriber overseeing your care does not reconstruct a three-month history from a 15-minute conversation. They review a continuous clinical record that shows the full between-visit picture.

This does not replace the clinical relationship. It makes it more accurate. The 7 things most patients skip are not skipped because patients do not care. They are skipped because the current system does not have a mechanism to collect them between appointments. That is the gap SiggyMD exists to close.

What Members Are Saying

T.A., 29 — Generalized Anxiety Disorder: “I had been telling my prescriber everything was fine for three months. My daily check-in data showed that my sleep quality had dropped after a dose change and had not recovered. My prescriber flagged it. I would not have brought it up because I did not think to connect the sleep to the medication.”

R.M., 44 — Major Depressive Disorder: “I had missed about two weeks of doses but I was embarrassed to say so. When I finally told my prescriber, she said it explained exactly what we were seeing in my check-in data and that my dose was actually working. I had just been taking it inconsistently. Knowing that changed everything.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

The quarterly appointment gives you 15 minutes. Most of what your prescriber needs to manage your medication accurately does not fit in 15 minutes, which means most of it does not get reported.

The 7 things listed here are not obvious or intuitive. They are the specific categories of information that change clinical decisions and that tend to get lost in the gap between appointments. Filling that gap, whether through structured self-tracking or a care model built for continuity, is what makes psychiatric medication work as well as it can.

Sources

1. Rossom RC, et al. Antidepressant Adherence Across Diverse Populations and Healthcare Settings. Depression and Anxiety. 2016;33(8):765-774.
2. Srimongkon P, Aslani P, Chen TF. Consumer-related factors influencing antidepressant adherence in unipolar depression: a qualitative study. Patient Preference and Adherence. 2018;12:1863-1873.
3. Vaughn SE, Strawn JR, et al. The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Journal of Personalized Medicine. 2021;11(7):615.
4. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. Journal of General Internal Medicine. 2001;16(9):606-613.
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed June 2026.
6. National Center for Complementary and Integrative Health. Known Science: Drug Interactions. NIH NCCIH. Accessed June 2026.
7. National Institute of Mental Health. Depression. NIMH. Accessed June 2026.
8. U.S. Food and Drug Administration. Drug Interactions: Table of Substrates, Inhibitors, and Inducers. FDA. Accessed June 2026.